Volitionrx Ltd (VNRX) Stock Analysis and Metrics

Volitionrx

NYSE: VNRX

$1.01 ▼ -0.07 (-6.48%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap109,643.10

P/E-0.02

P/S0.07

Div. Yield0.00

Total Debt (Qtr)6.71 Mn

Revenue Growth (1y) (Qtr)203.93

Add ratio to table…

About

VolitionRx Limited is a multi-national epigenetics company that develops simple, cost-effective blood tests for the early detection and monitoring of life-altering diseases such as cancer and sepsis. The firm’s proprietary technologies focus on chromosomal structures including nucleosomes and transcription factors as biomarkers in blood samples. VolitionRx Limited’s product portfolio includes the Nu. Q® Vet, Nu. Q® NETs, Nu. Q® Discover, Nu. Q® Cancer, and Capture-Seq™/Capture-PCR™ platforms, which are designed to work in manual, automated, and point-of-care settings. The company operates research, manufacturing, and commercial facilities in Belgium, the United States, and the United Kingdom, supported by a global team of over 75 employees. VolitionRx Limited seeks to improve patient outcomes while reducing healthcare costs through non-invasive blood-based diagnostics.

VolitionRx Limited generates revenue through the sale of diagnostic kits and reagents, licensing of its intellectual property, milestone and royalty payments from partners, and service fees for its Nu. Q® Discover profiling offering. The company sells its Nu. Q® Vet Cancer Test to veterinary distributors such as Antech Diagnostics, IDEXX Laboratories, and Fujifilm Vet Systems, and its Nu. Q® NETs assay to hospital laboratories and clinical institutions. Licensing agreements with firms like Werfen, Hologic, and Revvity provide upfront payments, milestone payments, and ongoing royalties. Additionally, VolitionRx Limited earns revenue from the sale of Capture-Seq™/Capture-PCR™ kits and related components to research and diagnostic partners. The firm also pursues reimbursement pathways for its CE-marked Nu. Q® NETs test and upcoming Nu. Q® Lung Cancer assay to drive recurring sales.

The company operates through the following segments:

• Nu. Q Vet: This segment provides blood-based cancer screening tests for dogs and other companion animals, including the Nu. Q® Vet Cancer Test sold through distributors such as Antech, IDEXX, and Fujifilm Vet Systems, and supports research into feline applications and NETosis detection in canines.

• Nu. Q NETs: This segment offers a CE-marked assay to quantify circulating Neutrophil Extracellular Traps for the detection and monitoring of sepsis and related conditions, compatible with central laboratory and point-of-care workflows.

• Nu. Q Discover: This segment delivers a nucleosome profiling service for drug developers and scientists, enabling epigenetic analysis in disease model development, preclinical testing, and clinical studies.

• Nu. Q Cancer: This segment supplies a range of blood-based assays for cancer screening, diagnosis, therapy selection, treatment monitoring, and minimal residual disease detection, with an initial focus on lung cancer.

• Capture-Seq™/Capture-PCR™: This segment provides a wet chemistry platform that isolates tumor-derived circulating DNA fragments from blood for rapid, cost-effective liquid biopsy analysis using qPCR or sequencing.

VolitionRx Limited occupies a niche within the epigenetics and liquid biopsy markets, competing with larger diagnostics firms such as Exact Sciences, Guardant Health, GRAIL, Natera, Roche Diagnostics, and Thermo Fisher Scientific, while differentiating itself through its focus on nucleosome-based biomarkers, low-cost assay formats, and platform agnostic designs that integrate with existing laboratory equipment. The company’s competitive advantages stem from its broad patent portfolio covering Nucleosomics™, Capture-PCR™, and Capture-Seq™ technologies, its ability to serve both human and veterinary markets, and its strategy of partnering with established diagnostic corporations to leverage their sales and distribution networks.

VolitionRx Limited’s customer base includes veterinary distributors and clinics, hospital laboratories, pharmaceutical and biotechnology companies, and academic research institutions. Specific customers named in the filing are Antech Diagnostics, IDEXX Laboratories, Fujifilm Vet Systems, Vita Genomics, DNA Tech, Nationwide Laboratories, The Veterinary Pathology Group, Heska (now part of Antech), Werfen, Hologic, Revvity, Immunodiagnostic Systems, and the Hospices Civils de Lyon hospital system in France. The company also serves reference laboratories, point-of-care testing sites, and clinical trial sponsors seeking epigenetic profiling services.

Investment Thesis

▲ Bull case

VolitionRx (VNRX) is positioned for transformative growth through its breakthrough Capture-Seq™ technology, which isolates >99% pure circulating tumor-derived DNA (ctDNA) by removing healthy cell background noise—a world-first achievement in liquid biopsy that addresses the industry's core limitation. This innovation enables detection of minimal residual disease (MRD) and multi-cancer early detection (MCED) with unprecedented specificity, positioning Volition to capture a share of the $23 billion annualized human MCED TAM and $13 billion MRD TAM. The technology has already generated significant interest from large diagnostic and liquid biopsy companies, with active discussions underway for licensing and co-development, suggesting near-term revenue inflection points through upfront fees, milestones, and royalties that are not yet priced into the stock given the company's current market capitalization and liquidity concerns.
The company's Nu.Q® NETs assay is gaining traction across multiple high-value clinical indications beyond sepsis, including Hidradenitis Suppurativa (HS)—a chronic neutrophilic disease affecting ~1% of the global population with a $3.8 billion TAM—and trauma-induced venous thromboembolism (VTE), validated in a Mayo Clinic-led study of 674 patients. These expansions are supported by CE marking for clinical use in 30 European countries and the UK, with real-world interventional programs like France's $7.3 million government-backed sepsis study driving adoption. Management's emphasis on precision medicine applications—such as guiding biologic therapy initiation and cessation in HS—creates sticky, recurring revenue potential from clinician reliance on the test for treatment monitoring, a catalyst underappreciated by the market focused solely on near-term revenue lines.
VolitionRx has secured non-dilutive funding exceeding $25 million from Belgian agencies (Namur Invest and Wallonie Entreprendre S.A.), reducing reliance on dilutive equity financing while advancing regulatory transitions (IVDD to IVDR for Nu.Q® NETs) and lateral flow prototype development for point-of-care sepsis testing in low-income countries. This financial anchor, combined with the NYSE American's acceptance of its compliance plan on April 22, 2026, removes an overhang of delisting risk and provides runway to achieve key milestones: French reimbursement for Nu.Q® Lung Cancer by Q4 2026, unlocking access to ~50,000 annual new lung cancer cases, and the anticipated $5 million milestone payment from the feline lymphoma assay publication. These de-risking events are not reflected in the current valuation, which remains depressed due to liquidity fears despite tangible progress toward cash flow break-even.
The veterinary segment, particularly the Nu.Q® Vet Cancer Test for dogs, is scaling rapidly with Fujifilm Vet Systems' centralized lab automation in Japan enabling high-throughput screening across 1,700+ registered veterinary hospitals serving ~7 million pet dogs. The recent feline lymphoma assay breakthrough—achieving 86% sensitivity at 97% specificity—creates a platform opportunity to double the companion animal TAM (currently estimated at $1.0+ billion) by addressing the significant unmet need in feline oncology, where early detection is historically poor due to invasive diagnostic barriers. Licensing discussions with over a dozen global diagnostic leaders across human and veterinary pillars suggest diversified revenue streams are imminent, yet the market overlooks this diversification as a buffer against reliance on any single product or geography.
Despite reporting losses, VolitionRx demonstrated 300% Q1 revenue growth (as highlighted in the May 27, 2026 corporate update) and $5 million veterinary milestone advancement, indicating accelerating commercialization momentum that contradicts the narrative of a stagnant pre-revenue biotech. The company's strategy of licensing its platform to large partners with installed lab infrastructure—rather than building direct sales forces—leverages third-party scale for rapid market penetration, a capital-efficient model that could yield disproportionate returns as licensing deals mature. This approach, combined with expanding IP protection (including the Ebola virus triage patent filing), creates durable competitive advantages that are not yet reflected in the stock price, which continues to trade at a discount to peers despite having multiple near-term catalysts with quantifiable financial impact.

VolitionRx (VNRX) is positioned for transformative growth through its breakthrough Capture-Seq™ technology, which isolates >99% pure circulating tumor-derived DNA (ctDNA) by removing healthy cell background noise—a world-first achievement in liquid biopsy that addresses the industry's core limitation. This innovation enables detection of minimal residual disease (MRD) and multi-cancer early detection (MCED) with unprecedented specificity, positioning Volition to capture a share of the $23 billion annualized human MCED TAM and $13 billion MRD TAM. The technology has already generated significant interest from large diagnostic and liquid biopsy companies, with active discussions underway for licensing and co-development, suggesting near-term revenue inflection points through upfront fees, milestones, and royalties that are not yet priced into the stock given the company's current market capitalization and liquidity concerns.
The company's Nu.Q® NETs assay is gaining traction across multiple high-value clinical indications beyond sepsis, including Hidradenitis Suppurativa (HS)—a chronic neutrophilic disease affecting ~1% of the global population with a $3.8 billion TAM—and trauma-induced venous thromboembolism (VTE), validated in a Mayo Clinic-led study of 674 patients. These expansions are supported by CE marking for clinical use in 30 European countries and the UK, with real-world interventional programs like France's $7.3 million government-backed sepsis study driving adoption. Management's emphasis on precision medicine applications—such as guiding biologic therapy initiation and cessation in HS—creates sticky, recurring revenue potential from clinician reliance on the test for treatment monitoring, a catalyst underappreciated by the market focused solely on near-term revenue lines.
VolitionRx has secured non-dilutive funding exceeding $25 million from Belgian agencies (Namur Invest and Wallonie Entreprendre S.A.), reducing reliance on dilutive equity financing while advancing regulatory transitions (IVDD to IVDR for Nu.Q® NETs) and lateral flow prototype development for point-of-care sepsis testing in low-income countries. This financial anchor, combined with the NYSE American's acceptance of its compliance plan on April 22, 2026, removes an overhang of delisting risk and provides runway to achieve key milestones: French reimbursement for Nu.Q® Lung Cancer by Q4 2026, unlocking access to ~50,000 annual new lung cancer cases, and the anticipated $5 million milestone payment from the feline lymphoma assay publication. These de-risking events are not reflected in the current valuation, which remains depressed due to liquidity fears despite tangible progress toward cash flow break-even.
The veterinary segment, particularly the Nu.Q® Vet Cancer Test for dogs, is scaling rapidly with Fujifilm Vet Systems' centralized lab automation in Japan enabling high-throughput screening across 1,700+ registered veterinary hospitals serving ~7 million pet dogs. The recent feline lymphoma assay breakthrough—achieving 86% sensitivity at 97% specificity—creates a platform opportunity to double the companion animal TAM (currently estimated at $1.0+ billion) by addressing the significant unmet need in feline oncology, where early detection is historically poor due to invasive diagnostic barriers. Licensing discussions with over a dozen global diagnostic leaders across human and veterinary pillars suggest diversified revenue streams are imminent, yet the market overlooks this diversification as a buffer against reliance on any single product or geography.
Despite reporting losses, VolitionRx demonstrated 300% Q1 revenue growth (as highlighted in the May 27, 2026 corporate update) and $5 million veterinary milestone advancement, indicating accelerating commercialization momentum that contradicts the narrative of a stagnant pre-revenue biotech. The company's strategy of licensing its platform to large partners with installed lab infrastructure—rather than building direct sales forces—leverages third-party scale for rapid market penetration, a capital-efficient model that could yield disproportionate returns as licensing deals mature. This approach, combined with expanding IP protection (including the Ebola virus triage patent filing), creates durable competitive advantages that are not yet reflected in the stock price, which continues to trade at a discount to peers despite having multiple near-term catalysts with quantifiable financial impact.

▼ Bear case

VolitionRx (VNRX) faces an imminent and severe liquidity crisis that threatens its operational continuity, despite recent non-dilutive funding inflows. The company reported a net loss of $18.7 million in FY2025 and continues to burn cash at an unsustainable rate, with only temporary relief from the €2.0 million ($2.3 million) Walloon financing and $2.0 million Lind Global note—both of which add to debt obligations rather than generating free cash flow. The NYSE American's acceptance of its compliance plan merely delays an inevitable delisting trigger; achieving the required stockholders' equity threshold by August 6, 2027, necessitates either a massive revenue inflection (unproven at scale) or another dilutive equity raise at deeply discounted prices, which would severely impair existing shareholder value and is not credibly achievable given the lack of near-term, guaranteed revenue streams.
The company's much-touted Capture-Seq™ technology remains at the manuscript stage, with no peer-reviewed publication, regulatory clearance, or commercial licensing agreement in place—despite management's repeated claims of a $23 billion TAM and interest from "large diagnostic partners." The May 15, 2026 earnings call disclosed only "discussions at various stages" with no concrete terms, timelines, or financial commitments, suggesting the technology is far from monetization and may never overcome validation hurdles in large-scale clinical trials. Similarly, the Nu.Q® NETs assay, while CE-marked, has seen minimal real-world adoption outside of government-funded programs like France's sepsis study, with no evidence of voluntary hospital uptake or reimbursement-driven usage in major markets, casting doubt on the scalability of its $3.8 billion TAM estimate for sepsis and chronic indications.
Reimbursement pathways remain a critical and unproven bottleneck for VolitionRx's human diagnostics business. Despite active work with Hospices Civils de Lyon (HCL) on the Nu.Q® Lung Cancer dossier submission, the company has not secured coverage in any major European or U.S. market, and the French RIHN framework's five-month evaluation timeline—cited as enabling Q4 2026 routine use—is optimistic given historical delays in novel diagnostic reimbursement. Without reimbursement, adoption will remain limited to research settings or self-pay patients, neither of which supports the high-volume, recurring revenue model implied by management's licensing strategy, rendering the $5 million feline milestone and sepsis study participation as isolated events rather than precursors to sustainable commercialization.
The veterinary segment, while showing progress in Japan through Fujifilm Vet Systems, is geographically fragmented and dependent on single-partner rollouts that lack scalability. The Nu.Q® Vet Canine test's availability in "more than 20 countries" masks low penetration per market, and the feline assay's potential to "double the TAM" is speculative, given the absence of published field effectiveness data, veterinary association endorsements, or pricing strategy—factors critical to adoption in a price-sensitive market where pet owners routinely decline preventive screening. Furthermore, the company's reliance on reference laboratories (rather than point-of-care) limits accessibility, and no major global veterinary diagnostic player has committed to broad distribution, casting doubt on the achievability of the claimed $1.0+ billion veterinary TAM.
VolitionRx's intellectual property strategy, while expansive, creates fragmentation rather than focus, with simultaneous pursuits in human cancer (Nu.Q® Cancer), sepsis/NETs (Nu.Q® NETs), veterinary oncology (Nu.Q® Vet), research tools (Nu.Q® Discover), and now Ebola triage—diluting R&D resources and complicating regulatory pathways. The company's financial disclosures reveal no material recurring revenue from licensing, with all near-term cash inflows stemming from non-dilutive grants, debt financing, or milestone payments contingent on uncertain clinical or regulatory outcomes. This dependence on event-driven income, combined with a history of missed timelines (e.g., delayed feline test launch despite 2024 canine rollout), indicates a pattern of overpromising and underdelivering that erodes credibility with partners and investors alike, making the pursuit of large-scale licensing agreements increasingly unlikely without a proven, revenue-generating product in hand.

VolitionRx (VNRX) faces an imminent and severe liquidity crisis that threatens its operational continuity, despite recent non-dilutive funding inflows. The company reported a net loss of $18.7 million in FY2025 and continues to burn cash at an unsustainable rate, with only temporary relief from the €2.0 million ($2.3 million) Walloon financing and $2.0 million Lind Global note—both of which add to debt obligations rather than generating free cash flow. The NYSE American's acceptance of its compliance plan merely delays an inevitable delisting trigger; achieving the required stockholders' equity threshold by August 6, 2027, necessitates either a massive revenue inflection (unproven at scale) or another dilutive equity raise at deeply discounted prices, which would severely impair existing shareholder value and is not credibly achievable given the lack of near-term, guaranteed revenue streams.
The company's much-touted Capture-Seq™ technology remains at the manuscript stage, with no peer-reviewed publication, regulatory clearance, or commercial licensing agreement in place—despite management's repeated claims of a $23 billion TAM and interest from "large diagnostic partners." The May 15, 2026 earnings call disclosed only "discussions at various stages" with no concrete terms, timelines, or financial commitments, suggesting the technology is far from monetization and may never overcome validation hurdles in large-scale clinical trials. Similarly, the Nu.Q® NETs assay, while CE-marked, has seen minimal real-world adoption outside of government-funded programs like France's sepsis study, with no evidence of voluntary hospital uptake or reimbursement-driven usage in major markets, casting doubt on the scalability of its $3.8 billion TAM estimate for sepsis and chronic indications.
Reimbursement pathways remain a critical and unproven bottleneck for VolitionRx's human diagnostics business. Despite active work with Hospices Civils de Lyon (HCL) on the Nu.Q® Lung Cancer dossier submission, the company has not secured coverage in any major European or U.S. market, and the French RIHN framework's five-month evaluation timeline—cited as enabling Q4 2026 routine use—is optimistic given historical delays in novel diagnostic reimbursement. Without reimbursement, adoption will remain limited to research settings or self-pay patients, neither of which supports the high-volume, recurring revenue model implied by management's licensing strategy, rendering the $5 million feline milestone and sepsis study participation as isolated events rather than precursors to sustainable commercialization.
The veterinary segment, while showing progress in Japan through Fujifilm Vet Systems, is geographically fragmented and dependent on single-partner rollouts that lack scalability. The Nu.Q® Vet Canine test's availability in "more than 20 countries" masks low penetration per market, and the feline assay's potential to "double the TAM" is speculative, given the absence of published field effectiveness data, veterinary association endorsements, or pricing strategy—factors critical to adoption in a price-sensitive market where pet owners routinely decline preventive screening. Furthermore, the company's reliance on reference laboratories (rather than point-of-care) limits accessibility, and no major global veterinary diagnostic player has committed to broad distribution, casting doubt on the achievability of the claimed $1.0+ billion veterinary TAM.
VolitionRx's intellectual property strategy, while expansive, creates fragmentation rather than focus, with simultaneous pursuits in human cancer (Nu.Q® Cancer), sepsis/NETs (Nu.Q® NETs), veterinary oncology (Nu.Q® Vet), research tools (Nu.Q® Discover), and now Ebola triage—diluting R&D resources and complicating regulatory pathways. The company's financial disclosures reveal no material recurring revenue from licensing, with all near-term cash inflows stemming from non-dilutive grants, debt financing, or milestone payments contingent on uncertain clinical or regulatory outcomes. This dependence on event-driven income, combined with a history of missed timelines (e.g., delayed feline test launch despite 2024 canine rollout), indicates a pattern of overpromising and underdelivering that erodes credibility with partners and investors alike, making the pursuit of large-scale licensing agreements increasingly unlikely without a proven, revenue-generating product in hand.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password